Bortezomib consolidation post‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse-Reference-Cited by-同舟云学术

Bortezomib consolidation post‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse

Published:2018-11-20 Issue:5 Volume:185 Page:948-951
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Cohen Oliver C.¹^ORCID,Counsell Nicholas²,Rabin Neil¹,Popat Rakesh¹^ORCID,Owen Roger G.³,Popova Bilyana²,Schofield Oliver²,Clifton‐Hadley Laura²,Lyons‐Lewis Janet¹,Rawstron Andy³,Spence Christopher²,Tute Ruth M.³,Hughes Derralynn⁴,Moore Sally⁵,Smith Paul²,Yong Kwee L.⁶^ORCID

Affiliation:

1. Haematology University College London Hospitals NHS Foundation TrustLondon UK

2. Cancer Research UK and UCL Cancer Trials Centre LondonUK

3. Leeds Teaching Hospitals NHS Trust Leeds Leeds UK

4. Department of Haematology Royal Free HospitalLondonUK

5. Royal United Hospitals Bath UK

6. Cancer Institute UCL London UK

Funder

National Institute for Health Research

Publisher

Wiley

Subject